Form 4: Surgery Partners Officer Sells Shares for Tax Obligations

Jennifer Baldock, Chief Admin & Dev Officer of Surgery Partners, Inc., sold 5,798 shares of common stock to cover tax withholding obligations.

Summary

• Jennifer Baldock, Chief Admin & Dev Officer and Director of Surgery Partners, Inc. (SGRY), reported a sale of company common stock.
• The transaction involved the disposition of 5,798 shares of common stock on March 12, 2026.
• The shares were sold at a weighted average price of $13.17 per share.
• The sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock on March 4, 2026.
• Following this transaction, Baldock beneficially owns 326,474 shares of Surgery Partners, Inc. common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes following restricted stock vesting, which is a common occurrence for executives.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1(c) plan, indicating a planned and not discretionary sale.
• The sale was specifically for tax withholding obligations, which is a common and expected event following restricted stock vesting.
• Jennifer Baldock retains a significant beneficial ownership of 326,474 shares, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even for tax purposes, reduces the direct ownership stake of a key executive.

Risks

• No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes following restricted stock vesting are common across all industries, particularly for executives in publicly traded companies. This transaction by Surgery Partners' Chief Admin & Dev Officer is consistent with typical executive compensation practices and does not inherently signal a change in the company's operational or strategic trajectory within the healthcare services sector.

Comparison to Industry Standards

• This type of insider transaction, specifically a sale to cover tax obligations upon restricted stock vesting, is a standard practice for executives across various industries.
• For example, similar tax-related sales are frequently observed at companies like HCA Healthcare (HCA) or Tenet Healthcare (THC) when their executives' restricted stock units vest.
• The volume of shares sold (5,798) is relatively small compared to the executive's total holdings (326,474 shares remaining), which is typical for such tax-related dispositions and does not suggest a significant shift in confidence or strategy, unlike larger, discretionary sales seen in other contexts.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the executive retains a substantial stake, suggesting continued alignment. The sale is for tax purposes, not a signal of lack of confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an insider to cover tax obligations upon restricted stock vesting, executed under a Rule 10b5-1(c) plan. It does not reflect a change in the company's fundamentals or the executive's long-term outlook, nor does it provide new information that would warrant a change in investment recommendation. The executive retains a significant ownership stake.

Keywords

Surgery Partners, SGRY, Insider Trading, Form 4, Stock Sale, Jennifer Baldock, Restricted Stock, Tax Withholding, Corporate Officer